KPIs & Operating Metrics(New)
Growth Metrics

Amgen (AMGN) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Amgen (AMGN) over the last 17 years, with Q4 2025 value amounting to $1.3 billion.

  • Amgen's Net Income towards Common Stockholders rose 11259.97% to $1.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $7.7 billion, marking a year-over-year increase of 8853.3%. This contributed to the annual value of $7.7 billion for FY2025, which is 8853.3% up from last year.
  • Amgen's Net Income towards Common Stockholders amounted to $1.3 billion in Q4 2025, which was up 11259.97% from $3.2 billion recorded in Q3 2025.
  • Amgen's Net Income towards Common Stockholders' 5-year high stood at $3.2 billion during Q3 2025, with a 5-year trough of -$113.0 million in Q1 2024.
  • Over the past 5 years, Amgen's median Net Income towards Common Stockholders value was $1.5 billion (recorded in 2022), while the average stood at $1.5 billion.
  • As far as peak fluctuations go, Amgen's Net Income towards Common Stockholders crashed by 10397.75% in 2024, and later skyrocketed by 163097.35% in 2025.
  • Quarter analysis of 5 years shows Amgen's Net Income towards Common Stockholders stood at $1.9 billion in 2021, then fell by 14.9% to $1.6 billion in 2022, then tumbled by 52.54% to $767.0 million in 2023, then dropped by 18.25% to $627.0 million in 2024, then skyrocketed by 112.6% to $1.3 billion in 2025.
  • Its Net Income towards Common Stockholders was $1.3 billion in Q4 2025, compared to $3.2 billion in Q3 2025 and $1.4 billion in Q2 2025.